20.32
0.58 (2.94%)
| Previous Close | 19.74 |
| Open | 19.77 |
| Volume | 2,330,166 |
| Avg. Volume (3M) | 2,705,780 |
| Market Cap | 1,766,109,568 |
| Price / Sales | 14.61 |
| Price / Book | 14.15 |
| 52 Weeks Range | |
| Earnings Date | 3 Nov 2025 |
| Operating Margin (TTM) | -416.67% |
| Diluted EPS (TTM) | -3.85 |
| Total Debt/Equity (MRQ) | 160.71% |
| Current Ratio (MRQ) | 5.80 |
| Operating Cash Flow (TTM) | -286.52 M |
| Levered Free Cash Flow (TTM) | -169.65 M |
| Return on Assets (TTM) | -36.29% |
| Return on Equity (TTM) | -93.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Syndax Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.0 |
| Price Volatility | -5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | -0.20 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.29% |
| % Held by Institutions | 120.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 56.00 (BTIG, 175.59%) | Buy |
| Median | 39.00 (91.93%) | |
| Low | 33.00 (JP Morgan, 62.40%) | Buy |
| Average | 41.00 (101.77%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 15.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barclays | 24 Nov 2025 | 35.00 (72.24%) | Buy | 19.76 |
| 04 Nov 2025 | 22.00 (8.27%) | Buy | 15.35 | |
| JP Morgan | 12 Nov 2025 | 33.00 (62.40%) | Buy | 16.79 |
| UBS | 04 Nov 2025 | 38.00 (87.01%) | Buy | 15.35 |
| BTIG | 27 Oct 2025 | 56.00 (175.59%) | Buy | 13.11 |
| 19 Sep 2025 | 56.00 (175.59%) | Buy | 14.78 | |
| HC Wainwright & Co. | 27 Oct 2025 | 40.00 (96.85%) | Buy | 13.11 |
| 16 Oct 2025 | 40.00 (96.85%) | Buy | 15.05 | |
| Stifel | 10 Sep 2025 | 44.00 (116.54%) | Buy | 15.73 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOLDAN KEITH A. | - | 19.12 | -1,224 | -23,403 |
| Aggregate Net Quantity | -1,224 | |||
| Aggregate Net Value ($) | -23,403 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 19.12 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOLDAN KEITH A. | Officer | 01 Dec 2025 | Disposed (-) | 1,224 | 19.12 | 23,403 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |